Prospective, randomized, double-blinded, placebo-controlled clinical trial.
To evaluate whether 90-day subcutaneous injections with 20 μg teriparatide increases the volume and quality of the fusion mass compared to placebo based on 12-month postop fine cut computed tomography scans. The secondary objective is to evaluate whether parathyroid hormone (PTH) increases fusion rates compared to placebo.
Few studies have investigated the effects of PTH on fusion in patients undergoing spinal arthrodesis. Early studies showed a more robust fusion mass with PTH after spinal fusion surgery. But the efficiency of PTH on noninstrumented spinal fusion surgery remains unclear.
Patients with degenerative spondylolisthesis scheduled for noninstrumented posterolateral fusion were randomized to receive 90-day subcutaneous injections with 20 μg teriparatide (N = 41) or placebo (N = 46) in a 1:1 fashion. Fusion volume and quality was evaluated using 12-month postoperative fine cut computed tomography scans.
The two groups were comparable in terms of age, sex, and numbers of levels operated. PTH treatment was well tolerated but provided no additional benefit versus placebo. Fusion rates, the mean volume, and robustness of the fusion mass were similar between the PTH and placebo groups.
Ninety-day subcutaneous administration of 20 μg teriparatide did not increase fusion volume or improve the quality of the fusion mass in elderly patients compared to placebo after noninstrumented spinal fusion surgery for degenerative spondylolisthesis.
Level of Evidence: 1
This randomized double-blind placebo control trial showed that 90-day injections of parathyroid hormone did not improve fusion volume or quality in elderly patients with degenerative spondylolisthesis after noninstrumented spinal fusion compared to placebo.
∗Spine Surgery and Research, Spine Centre of Southern Denmark, Hospital Lillebaelt, Middelfart, Denmark
†Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Address correspondence and reprint requests to Annette Bennedsgaard Jespersen, MD, PhD, Spine Surgery and Research, Spine Centre of Southern Denmark, Hospital Lillebaelt, Østre Hougvej 55, DK-5500, Middelfart, Denmark; E-mail: firstname.lastname@example.org
Received 5 March, 2018
Revised 19 June, 2018
Accepted 22 June, 2018
The device(s)/drug(s) is/are FDA approved or approved by corresponding national agency for this indication.
Eli Lilly and Company funds were received in support of this work.
Relevant financial activities outside the submitted work: board membership, consultancy, employment, grants, travel/accommodations/meeting expenses.